Radiochromic film in vivo dosimetry predicts early the risk of acute skin toxicity for brachytherapy partial breast irradiation

2020 ◽  
Vol 65 (8) ◽  
pp. 085001
Author(s):  
Gerson M Struik ◽  
Jeremy Godart ◽  
Taco M Klem ◽  
Thalat T Monajemi ◽  
James Robar ◽  
...  
2015 ◽  
Vol 115 ◽  
pp. S85
Author(s):  
A. Petoukhova ◽  
I. Rüssel ◽  
J. Van Wingerden ◽  
P. Koper ◽  
A. Marinelli ◽  
...  

2017 ◽  
Vol 44 ◽  
pp. 26-33 ◽  
Author(s):  
Anna Petoukhova ◽  
Iris Rüssel ◽  
Julienne Nijst-Brouwers ◽  
Ko van Wingerden ◽  
Jaap van Egmond ◽  
...  

2021 ◽  
Author(s):  
Peiling Dai ◽  
Kai Chen ◽  
Lan Li ◽  
Li Wang ◽  
Yaoxiong Xia ◽  
...  

Abstract PurposePostoperative radiotherapy can reduce the recurrence of breast cancer. Postoperative radiotherapy is divided into whole breast irradiation (WBI) and partial breast irradiation (PBI) for early breast cancers. Due to the characters of saving time, money, and easy to deliver, external beams PBI (EB PBI) is brought into focus. However, the researches on outcomes, safety, and efficacy between EB PBI and WBI are still insufficient. We concluded a meta-analysis for LRR, regional node recurrence, contralateral breast cancer, distant recurrence, mortality, less acute skin toxicity (˃ 1 grade), late skin toxicity and the cosmetic score of external beam partial breast irradiation (EB PBI) and whole breast irradiation(WBI) to develop a radiotherapy plan for early low recurrence risk breast cancer patients. MethodWe searched Pubmed、Embase、Cochrane Library、Clinicaltrals. Study eligibility criteria are as below: (1) RCTs for EB PBI vs WBI; (2) Histologically confirmed breast cancer; (3) AJCC staged Tis-2N0-1M0; (4) ≥ 40 years old; (5) Tumor size ≤ 3 cm;(6) microscopically clear margins ≤ 5 cm; (7) Mean follow-up time༞5 years. All data is used by Cochrane’s Review Manager 5.3 (RevMan) to process.ResultsThere were 4 RCT studies included in our study with 1999 patients in EB PBI group and 1999 patients in EB PBI. There was no statistic difference between PBI and WBI groups in local recurrence rates (RR = 1.15; 95% CI, 0.76 to 1.74; p = 0.52; I2 = 0%), regional node recurrence(RR = 1.00; 95% CI, 0.49 to 2.04, p = 0.99, I2 = 0%), contralateral breast cancer (RR = 0.79; 95% CI, 0.54 to 1.16; p = 0.23; I2 = 0%), distant recurrence(RR = 1.00; 95% CI, 0.63 to 1.59; p = 1.00; I2 = 0%), non-breast second cancer (RR = 1.03; 95% CI, 0.50 to 2.16; p = 0.93; I2 = 83%), mortality(RR = 0.96; 95% CI, 0.60 to 1.55; p = 0.88, I2 = 54%). EB PBI had worse cosmetic score (RR = 1.56; 95% CI, 1.04 to 2.34; p = 0.003, I2 = 84%), less acute skin toxicity (˃ 1 grade) (RR = 0.17; 95% CI, 0.07 to 0.42; p༜ 0.0001, I2 = 87%) and late skin toxicity(RR = 0.65; 95% CI, 0.48 to 0.88; p = 0.005; I2 = 27%) than WBI.ConclusionEB PBI has similar LRR, regional node recurrence, contralateral breast cancer, distant recurrence, non-breast second cancer and mortality with WBI. But EB PBI has worse cosmetic score, less acute skin toxicity (˃ 1 grade) and late skin toxicity than WBI.


2011 ◽  
Vol 99 ◽  
pp. S11
Author(s):  
A. Petoukhova ◽  
K. van Wingerden ◽  
P. Koper ◽  
H. Ceha ◽  
A. Verbeek-de Kanter ◽  
...  

2016 ◽  
Author(s):  
◽  
Jason Stanford

[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT REQUEST OF AUTHOR.] Advance treatment techniques, such as IMRT and dynamic conformal arc delivery, are novel radiation treatment procedures at the forefront of accurate and precise radiotherapy. However, the risk of suboptimal treatment resulting in injury is far greater with these techniques due to their complexity. An in vivo quality assurance system is the most appropriate validation of the delivered dose to the patient from these techniques. The intent of this research is to propose an in vivo dosimetry quality assurance procedure using radiochromic film. This research proved that radiochromic in vivo dosimetry is a viable method of detecting spatial patient specific errors in radiotherapy; however, the process is time consuming and not sensitive enough for dosimetric errors associated with weight change. Although time consuming, in vivo radiochromic dosimetry is an attractive alternative for small cancer centers and developing countries without the large startup capital to acquire the electronic portal imaging device necessary for EPID in vivo dosimetry.


2013 ◽  
Vol 40 (9) ◽  
pp. 091716 ◽  
Author(s):  
Caleb Price ◽  
Aaron Pederson ◽  
Chanté Frazier ◽  
John Duttenhaver

Sign in / Sign up

Export Citation Format

Share Document